



Handwritten signature/initials

Case No. BP0308-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/751,388
Applicant(s) : Pappin et al.
Filed : 01/05/2004
TC/A.U. : 1626
Examiner : Sackey, Ebenezer O.
For : Isobarically Enriched N-Substituted Piperazines and Methods for the Preparation thereof
Customer No. : 23544

Confirmation No.:2659

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on	
Date of Deposit:	9-20-06
Signature:	<i>Patricia E. Tocci</i>
Type Name of Depositing Party:	Patricia E. Tocci

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO/SB/08A) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies a new patent application submitted herewith.
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.

- (d) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.
- (e) ☒ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**
- (f) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- ☐ Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the items on PTO/SB/08A that are not United States Publications:

☒ are supplied herewith

☐ are not supplied because they were previously cited by or submitted to the Office in prior application Serial No. _____, filed _____ and relied upon in this application for an earlier filing date under 35 USC §120.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: _____

9/20/06



Brian D. Gildea
Attorney for Applicants
Reg. No. 39,995
Telephone: 508-383-7632
Customer No.: 23544
Applied Biosystems
500 Old Connecticut Path
Framingham, MA 01701 USA

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE				Atty Docket No.		Application No.	
				BP0308-US		10/751,388	
REFERENCES CITED BY APPLICANTS				Applicant			
(Use several sheets if necessary)				Pappin, Darryl J.C. et al			
				Filing Date		Group	
				01/05/2004		1626	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AP	US05/0049406	03 March 2005	Lerchen et al			
	AQ	6,824,981	30 Nov 2004	Chait et al			
FOREIGN PATENT DOCUMENTS							
							TRANSLATION
		DOCUMENT Number	DATE	COUNTRY	CLASS	SUBCLASS	YES NO
	BQ	0209763	01 July 1986	EP			<input checked="" type="checkbox"/> <input type="checkbox"/>
	BR	WO04/086050	07 Oct 2004	WIPO			<input type="checkbox"/> x
	BS	WO01/68664	20 Sept 2001	WIPO			<input type="checkbox"/> x
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	GI	PCT International Search Report and Written Opinion mailed 10 August 2006					
	GJ	Bartlett Jones, M., et al., "Peptide Ladder Sequencing by Mass Spectrometry Using a Novel, Volatile Degradation Reagent", Rapid Communications in Mass Spectrometry, Vol 8, 737-742 (1994)					
	GK	Day, Richard et al, "N-Terminal Groups in Mass Spectrometry of Peptides. A Study Including Some New and Useful Derivatives", J. Org. Chem., Vol 38, No. 4, 1975 782-788					
	GL	Golding, Bernard T. et al. "Chemistry of Nitrogen Mustard [2-Chloro-N(2-chloroethyl)-N-methylethanamine] studied by Nuclear Magnetic Resonance Spectroscopy", J. Chem Soc. Perkin Trans. II 1987, pp 705-713					
	GM	Huang, Yulin et al, "A Method for High Efficiency Peptide Sequencing Using Combined Enzymatic Digestion and Chemical Derivatization on MALDI MSMS", Applied Biosystems Poster Number 1159					
	GN	Ross, Philip et al, "Investigation of Chemical Derivatization for Peptide CID Using LC-MALDI TOF MS/MS", Applied Biosystems Poster Number ThPF 250					
	GO	Roth, Kenneth et al, "Charge Derivatization of Peptides for Analysis by Mass Spectrometry", Mass Spectrometry Reviews, 1998, 17, 255-274					
	GP	Sherman, Nicholas et al, "A Novel N-Terminal Derivative Designed to Simplify Peptide Fragmentation", Proceedings of the 43rd ASMS Conference on Mass Spectrometry and Allied Topics, Atlanta, Georgia, May 21-26 1995, pp 626-627					

	GQ	Shetty, Umesha H. et al, "Piperazine Ring Cleavage in the Electron Impact Induced Fragmentation of Piperazine Type Phenothiazine Antipsychotic Agents", Biomedical Mass Spectrometry, Vol 10, No. 11, 1983, pp 601-607
Examiner		Date Considered
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>		